In his new role, he will be responsible for building the infrastructure needed for commercialization of the RI-002 product and other candidates. He will also be tasked with developing revenue and growth for ADMA as a whole.
ADMA also named Dr. Doris Connell as vice president, medical affairs, and Theresa Gwaltney as senior director, supply chain operations.
“As we continue to execute on our 2015 objectives, the addition of these key team members will each individually add valuable commercial expertise as we position ADMA for the commercialization of our lead product candidate, RI-002,” Adam Grossman, chief executive officer and president of ADMA, said in a prepared statement.
RI-002 is a specialty intravenous immune globulin product intended to treat patients with primary immune deficiency disease.